All Stories

  1. CETP Renaissance with Obicetrapib

    Article • Current Atherosclerosis Reports, April 2026, Springer Science + Business Media

    Dr Angela Pirillo

  2. From child to family: rethinking cascade screening for elevated Lipoprotein(a)

    Article • European Journal of Preventive Cardiology, March 2026, Oxford University Press (OUP)

    Dr Angela Pirillo

  3. Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice

    Article • Current Atherosclerosis Reports, February 2026, Springer Science + Business Media

    Dr Angela Pirillo

  4. Fibrates : Do They Still Have a Role in Therapy in 2025?

    Article • Current Atherosclerosis Reports, December 2025, Springer Science + Business Media

    Dr Angela Pirillo

  5. Apolipoprotein B at the core: another step forward

    Article • European Heart Journal, September 2025, Oxford University Press (OUP)

    Dr Angela Pirillo

  6. Lipoprotein (a): A new target for pharmacological research and an option for treatment

    Article • European Journal of Internal Medicine, September 2025, Elsevier

    Dr Angela Pirillo

  7. PCSK9 reloaded: sirtuin-1 as a post-translational checkpoint for LDL-C control

    Article • Cardiovascular Research, July 2025, Oxford University Press (OUP)

    Dr Angela Pirillo

  8. Beyond the mean: the prognostic value of lipid variability in atherosclerosis and mortality

    Article • European Journal of Preventive Cardiology, May 2025, Oxford University Press (OUP)

    Dr Angela Pirillo

  9. Oral PCSK9 Inhibitors: Will They Work?

    Article • Current Atherosclerosis Reports, April 2025, Springer Science + Business Media

    Dr Angela Pirillo

  10. Apolipoprotein C3 and cardiovascular risk: new insights from the ODYSSEY outcomes trial

    Article • European Journal of Preventive Cardiology, April 2025, Oxford University Press (OUP)

    Dr Angela Pirillo

  11. LDL-cholesterol goal attainment with ezetimibe and bempedoic acid in patients at high and very-high cardiovascular risk: A simulation study in the Italian cohort of the SANTORINI study

    Article • European Atherosclerosis Journal, December 2024, S.I.Te.C.S Societa Italiana di Terapia Clinica e Sperimentale

    Dr Angela Pirillo

  12. Can apoA-I infusion decrease cardiovascular events?

    Article • European Heart Journal, November 2024, Oxford University Press (OUP)

    Dr Angela Pirillo

  13. Saturated vs. unsaturated fatty acids: should we reconsider their cardiovascular effects?

    Article • European Journal of Preventive Cardiology, November 2024, Oxford University Press (OUP)

    Dr Angela Pirillo

  14. In memoriam: Akira Endo

    Article • European Heart Journal, August 2024, Oxford University Press (OUP)

    Dr Angela Pirillo

  15. Proprotein convertase subtilisisn/kexin type 9 inhibitors: the earlier the better?

    Article • European Journal of Preventive Cardiology, June 2024, Oxford University Press (OUP)

    Dr Angela Pirillo

  16. European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges

    Article • Current Atherosclerosis Reports, March 2024, Springer Science + Business Media

    Dr Angela Pirillo

  17. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance

    Article • Cardiovascular Research, December 2023, Oxford University Press (OUP)

    Dr Angela Pirillo

  18. How to Handle Elevated Triglycerides: Life after PROMINENT

    Article • Current Atherosclerosis Reports, December 2023, Springer Science + Business Media

    Dr Angela Pirillo

  19. Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials

    Article • European Heart Journal, November 2023, Oxford University Press (OUP)

    Dr Angela Pirillo

  20. PCSK9 in extrahepatic tissues: What can we expect from its inhibition?

    Article • European Atherosclerosis Journal, August 2023, S.I.Te.C.S Societa Italiana di Terapia Clinica e Sperimentale

    Dr Angela Pirillo

  21. Glycerol and β-hydroxybutyrate: friends or foes?

    Article • European Heart Journal, August 2023, Oxford University Press (OUP)

    Dr Angela Pirillo

  22. Cardiovascular risk assessment: are we getting all the information we need?

    Article • European Journal of Preventive Cardiology, July 2023, Oxford University Press (OUP)

    Dr Angela Pirillo

  23. The burden of hypercholesterolemia and ischemic heart disease in an ageing world

    Article • Pharmacological Research, July 2023, Elsevier

    Dr Angela Pirillo

  24. Lipid-lowering treatment and LDL-C goal attainment in high and very high cardiovascular risk patients: Evidence from the SANTORINI study-The Italian experience

    Article • European Atherosclerosis Journal, April 2023, S.I.Te.C.S Societa Italiana di Terapia Clinica e Sperimentale

    Dr Angela Pirillo

  25. Remnant cholesterol: a reliable prognostic marker?

    Article • European Journal of Preventive Cardiology, April 2023, Oxford University Press (OUP)

    Dr Angela Pirillo

  26. Lp(a) as a Cardiovascular Risk Factor

    Article • January 2023, Springer Science + Business Media

    Dr Angela Pirillo

  27. Inclisiran: How Widely and When Should We Use It?

    Article • Current Atherosclerosis Reports, July 2022, Springer Science + Business Media

    Dr Angela Pirillo

  28. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia

    Article • Expert Opinion on Biological Therapy, June 2022, Taylor & Francis

    Dr Angela Pirillo

  29. Twelve Variants Polygenic Score for Low‐Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations

    Article • Journal of the American Heart Association, April 2022, Wolters Kluwer Health

    Dr Angela Pirillo, Dr Giuseppe Marco Tina

  30. Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia

    Article • European Journal of Preventive Cardiology, February 2022, Oxford University Press (OUP)

    Dr Angela Pirillo

  31. New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia

    Article • Current Opinion in Endocrinology Diabetes and Obesity, January 2022, Wolters Kluwer Health

    Dr Angela Pirillo

  32. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors

    Article • Current Atherosclerosis Reports, October 2021, Springer Science + Business Media

    Dr Angela Pirillo

  33. Lipoprotein remnants: to be or not to be

    Article • European Heart Journal, August 2021, Oxford University Press (OUP)

    Dr Angela Pirillo

  34. Omega-3 for Cardiovascular Diseases: Where Do We Stand After REDUCE-IT and STRENGTH?

    Article • Circulation, July 2021, Wolters Kluwer Health

    Dr Angela Pirillo

  35. HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases

    Article • Cells, April 2021, MDPI AG

    Dr Angela Pirillo

  36. Global epidemiology of dyslipidaemias

    Article • Nature Reviews Cardiology, April 2021, Springer Science + Business Media

    Dr Angela Pirillo

  37. Recent insights into low-density lipoprotein metabolism and therapy

    Article • Current Opinion in Clinical Nutrition & Metabolic Care, December 2020, Wolters Kluwer Health

    Dr Angela Pirillo

  38. Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients

    Article • Atherosclerosis Supplements, December 2020, Elsevier

    Dr Angela Pirillo

  39. Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy

    Article • Atherosclerosis Supplements, December 2020, Elsevier

    Dr Angela Pirillo

  40. Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives

    Article • Atherosclerosis Supplements, December 2020, Elsevier

    Dr Angela Pirillo

  41. Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool

    Article • Atherosclerosis Supplements, December 2020, Elsevier

    Dr Angela Pirillo

  42. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project

    Article • Atherosclerosis Supplements, December 2020, Elsevier

    Dr Angela Pirillo

  43. Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk

    Article • Atherosclerosis Supplements, December 2020, Elsevier

    Dr Angela Pirillo

  44. Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years

    Article • Clinical Chemistry, November 2020, Oxford University Press (OUP)

    Dr Angela Pirillo

  45. Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors

    Article • European Journal of Preventive Cardiology, November 2020, Oxford University Press (OUP)

    Dr Angela Pirillo

  46. The cardiovascular benefit of Lp(a) reduction: not there yet

    Article • European Heart Journal, November 2020, Oxford University Press (OUP)

    Dr Angela Pirillo

  47. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction

    Article • Current Atherosclerosis Reports, October 2020, Springer Science + Business Media

    Dr Angela Pirillo

  48. Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis

    Article • Cardiovascular Research, September 2020, Oxford University Press (OUP)

    Dr Angela Pirillo

  49. New Pharmacological Approaches to Target PCSK9

    Article • Current Atherosclerosis Reports, June 2020, Springer Science + Business Media

    Dr Angela Pirillo

  50. Insights from ORION studies: focus on inclisiran safety

    Article • Cardiovascular Research, May 2020, Oxford University Press (OUP)

    Dr Angela Pirillo

  51. Beyond LDL-C levels, does remnant cholesterol estimation matter?

    Article • European Journal of Preventive Cardiology, February 2020, SAGE Publications

    Professor Alberico L. Catapano, Dr Angela Pirillo

  52. LDL-Cholesterol-Lowering Therapy

    Article • January 2020, Springer Science + Business Media

    Dr Angela Pirillo

  53. Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects

    Article • Atherosclerosis, November 2019, Elsevier

    Dr Angela Pirillo

  54. Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation

    Article • Current Opinion in Lipidology, October 2019, Wolters Kluwer Health

    Dr Angela Pirillo

  55. Cholesterol metabolism, pancreatic β-cell function and diabetes

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, September 2019, Elsevier

    Dr Angela Pirillo

  56. The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion

    Article • Atherosclerosis Supplements, August 2019, Elsevier

    Dr Angela Pirillo

  57. Statins increase Lp(a) plasma level: is this clinically relevant?

    Article • European Heart Journal, July 2019, Oxford University Press (OUP)

    Professor Alberico L. Catapano, Dr Angela Pirillo

  58. Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation

    Article • Stroke, July 2019, Wolters Kluwer Health

    Dr Angela Pirillo

  59. Biological Consequences of Dysfunctional HDL

    Article • Current Medicinal Chemistry, May 2019, Bentham Science Publishers

    Dr Angela Pirillo, Professor Alberico L. Catapano

  60. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials

    Article • Pharmacological Research, May 2019, Elsevier

    Dr Angela Pirillo

  61. Novel strategies to target PCSK9: beyond monoclonal antibodies

    Article • Cardiovascular Research, January 2019, Oxford University Press (OUP)

    Professor Alberico L. Catapano, Dr Angela Pirillo

  62. Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?

    Article • European Journal of Preventive Cardiology, December 2018, SAGE Publications

    Professor Alberico L. Catapano, Dr Angela Pirillo

  63. Lipid Lowering and Incidence of Cataract, a Role for Fibrates

    Article • Clinical Pharmacology & Therapeutics, December 2018, Wiley

    Dr Angela Pirillo

  64. High-density lipoprotein cholesterol levels, cardiovascular disease risk, and cancer: a relation which does not apply to all?

    Article • Cardiovascular Research, October 2018, Oxford University Press (OUP)

    Dr Angela Pirillo

  65. Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study

    Article • Atherosclerosis, October 2018, Elsevier

    Dr Angela Pirillo

  66. PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?

    Article • European Heart Journal, June 2018, Oxford University Press (OUP)

    Dr Angela Pirillo

  67. Proprotein Convertase Subtilisin Kexin 9 Inhibitors

    Article • Cardiology Clinics, May 2018, Elsevier

    Dr Angela Pirillo

  68. The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis

    Article • Current Atherosclerosis Reports, February 2018, Springer Science + Business Media

    Dr Angela Pirillo

  69. Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey

    Article • International Journal of Cardiology, February 2018, Elsevier

    Dr Angela Pirillo

  70. Familial Hypercholesterolemia

    Article • January 2018, Elsevier

    Dr Angela Pirillo

  71. Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?

    Article • Molecular Therapy, November 2017, Elsevier

    Dr Angela Pirillo

  72. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study

    Article • Atherosclerosis Supplements, October 2017, Elsevier

    Dr Angela Pirillo

  73. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

    Article • Vascular Health and Risk Management, September 2017, Dove Medical Press

    Professor Alberico L. Catapano, Dr Angela Pirillo

  74. Strategies for the use of nonstatin therapies

    Article • Current Opinion in Lipidology, September 2017, Wolters Kluwer Health

    Dr Angela Pirillo

  75. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies

    Article • Atherosclerosis, August 2017, Elsevier

    Dr Angela Pirillo

  76. Effect of PSCK9 loss-of-function mutation R46l on plasma lipids, endothelial function and vascular inflammation in the post-prandial state

    Article • Atherosclerosis, August 2017, Elsevier

    Dr Angela Pirillo

  77. PCSK9 inhibition in statin-intolerant HeFH patients: What’s new?

    Article • European Journal of Preventive Cardiology, July 2017, SAGE Publications

    Professor Alberico L. Catapano, Dr Angela Pirillo

  78. Pitavastatin and HDL: Effects on plasma levels and function(s)

    Article • Atherosclerosis Supplements, July 2017, Elsevier

    Dr Angela Pirillo

  79. Vascular inflammation and low‐density lipoproteins: is cholesterol the link? A lesson from the clinical trials

    Article • British Journal of Pharmacology, May 2017, Wiley

    Dr Angela Pirillo

  80. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies

    Article • Nutrition Metabolism and Cardiovascular Diseases, May 2017, Elsevier

    Dr Angela Pirillo

  81. Familial Hypercholesterolemia

    Article • January 2017, Elsevier

    Dr Angela Pirillo

  82. Advances in Hypercholesterolemia

    Article • January 2017, Elsevier

    Dr Angela Pirillo

  83. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering

    Article • Cardiovascular Research, August 2016, European Society of Cardiology

    Dr Angela Pirillo

  84. Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases

    Article • Current Medicinal Chemistry, April 2016, Bentham Science Publishers

    Dr Angela Pirillo

  85. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies

    Article • Atherosclerosis, December 2015, Elsevier

    Dr Angela Pirillo

  86. Apolipoprotein C-III: From Pathophysiology to Pharmacology

    Article • Trends in Pharmacological Sciences, October 2015, Elsevier

    Dr Angela Pirillo

  87. Mutazioni del gene APOC3, metabolismo dei trigliceridi e riduzione di eventi ischemici cardiovascolari

    Article • Giornale Italiano di Cardiologia, May 2015, Il Pensiero Scientifico Editore

    Dr Angela Pirillo

  88. Statin Intolerance: Diagnosis and Remedies

    Article • Current Cardiology Reports, April 2015, Springer Science + Business Media

    Dr Angela Pirillo

  89. Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3

    Article • Drug Design Development and Therapy, April 2015, Taylor & Francis

    Professor Alberico L. Catapano, Dr Angela Pirillo

  90. Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?

    Article • January 2015, Springer Science + Business Media

    Dr Angela Pirillo

  91. HDL in Infectious Diseases and Sepsis

    Article • December 2014, Springer Science + Business Media

    Dr Angela Pirillo

  92. Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus

    Article • Nutrition Metabolism and Cardiovascular Diseases, July 2014, Elsevier

    Dr Angela Pirillo

  93. HDL in innate and adaptive immunity

    Article • Cardiovascular Research, June 2014, European Society of Cardiology

    Professor Alberico L. Catapano, Dr Angela Pirillo

  94. HDL: To Treat or Not To Treat?

    Article • Current Atherosclerosis Reports, June 2014, Springer Science + Business Media

    Dr Angela Pirillo

  95. Postprandial lipemia as a cardiometabolic risk factor

    Article • Current Medical Research and Opinion, May 2014, Informa Healthcare

    Dr Angela Pirillo

  96. 15-Lipoxygenase-Mediated Modification of HDL3 Impairs eNOS Activation in Human Endothelial Cells

    Article • Lipids, February 2014, Wiley

    Dr Angela Pirillo

  97. Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia

    Article • International Journal of Cardiology, December 2013, Elsevier

    Dr Angela Pirillo

  98. Prevalence of classical CD14++/CD16− but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia

    Article • International Journal of Cardiology, October 2013, Elsevier

    Dr Angela Pirillo

  99. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia

    Article • Atherosclerosis Supplements, August 2013, Elsevier

    Dr Angela Pirillo

  100. Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States

    Article • July 2013, Springer Science + Business Media

    Dr Angela Pirillo

  101. Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality

    Article • Current Pharmaceutical Design, April 2013, Bentham Science Publishers

    Dr Angela Pirillo

  102. LOX-1, OxLDL, and Atherosclerosis

    Article • Mediators of Inflammation, January 2013, Hindawi Publishing Corporation

    Dr Angela Pirillo

  103. High-Density Lipoprotein Subfractions - What the Clinicians Need to Know

    Article • Cardiology, January 2013, Karger Publishers

    Dr Angela Pirillo

  104. Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases

    Article • Disease Markers, January 2013, Hindawi Publishing Corporation

    Dr Angela Pirillo

  105. Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins

    Article • Biochemical and Biophysical Research Communications, November 2012, Elsevier

    Dr Angela Pirillo

  106. Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia

    Article • European Journal of Clinical Pharmacology, July 2012, Springer Science + Business Media

    Dr Angela Pirillo

  107. Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models

    Article • Journal of the American Heart Association, June 2012, Wolters Kluwer Health

    Dr Angela Pirillo

  108. Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models

    Article • Journal of the American Heart Association, February 2012, Wolters Kluwer Health

    Dr Angela Pirillo

  109. Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population

    Article • PLOS One, February 2012, PLOS

    Dr Angela Pirillo

  110. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

    Article • Atherosclerosis, February 2012, Elsevier

    Dr Angela Pirillo

  111. Emerging role of high density lipoproteins as a player in the immune system

    Article • Atherosclerosis, January 2012, Elsevier

    Dr Angela Pirillo

  112. HDLs, immunity, and atherosclerosis

    Article • Current Opinion in Lipidology, October 2011, Wolters Kluwer Health

    Dr Angela Pirillo

  113. Therapy and clinical trials

    Article • Current Opinion in Lipidology, August 2011, Wolters Kluwer Health

    Dr Angela Pirillo

  114. Statins prevent tissue factor induction by protease-activated receptors 1 and 2 in human umbilical vein endothelial cells in vitro

    Article • Journal of Thrombosis and Haemostasis, August 2011, Wiley

    Dr Angela Pirillo

  115. Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells

    Article • Atherosclerosis, February 2011, Elsevier

    Dr Angela Pirillo

  116. Dual effect of hypochlorite in the modification of high density lipoproteins

    Article • Biochemical and Biophysical Research Communications, December 2010, Elsevier

    Dr Angela Pirillo

  117. The Challenge of Lipid Management in Patients with Diabetes or Other Endocrine Disorders

    Article • touchREVIEWS in Endocrinology, January 2010, Touch Digital Media, Ltd.

    Dr Angela Pirillo

  118. The 15-lipoxygenase-modified HDL3 fail to inhibit the TNF- -induced inflammatory response in human endothelial cells

    Article • The Journal of Immunology, December 2008, The American Association of Immunologists

    Dr Angela Pirillo

  119. The 15-Lipoxygenase-Modified High Density Lipoproteins 3 Fail to Inhibit the TNF- -Induced Inflammatory Response in Human Endothelial Cells

    Article • The Journal of Immunology, August 2008, The American Association of Immunologists

    Dr Angela Pirillo

  120. EFFECTS OF NATIVE AND MODIFIED HDL ON HUMAN IMMUNE FUNCTIONS

    Article • Atherosclerosis Supplements, May 2008, Elsevier

    Dr Angela Pirillo

  121. Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells

    Article • Arteriosclerosis Thrombosis and Vascular Biology, January 2008, Wolters Kluwer Health

    Dr Angela Pirillo

  122. Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux

    Article • Cardiovascular Research, August 2007, European Society of Cardiology

    Dr Angela Pirillo

  123. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice

    Article • Atherosclerosis, April 2007, Elsevier

    Dr Angela Pirillo

  124. Modified HDL: Biological and physiopathological consequences

    Article • Nutrition Metabolism and Cardiovascular Diseases, July 2006, Elsevier

    Dr Angela Pirillo

  125. 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages

    Article • Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, March 2006, Elsevier

    Dr Angela Pirillo

  126. In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels

    Article • International Journal of Molecular Medicine, February 2006, Spandidos Publications

    Dr Angela Pirillo

  127. Th-P15:162 15-Lipoxygenase-mediated modification of high density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages

    Article • Atherosclerosis Supplements, January 2006, Elsevier

    Dr Angela Pirillo

  128. Proteome of endothelial cell-derived procoagulant microparticles

    Article • PROTEOMICS, October 2005, Wiley

    Dr Angela Pirillo

  129. Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization

    Article • British Journal of Haematology, September 2004, Wiley

    Dr Angela Pirillo

  130. Native LDL and Oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF-κB, CRE dependent pathway and affect PGE2 synthesis

    Article • International Journal of Molecular Medicine, September 2004, Spandidos Publications

    Dr Angela Pirillo

  131. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL

    Article • Cardiovascular Research, July 2003, European Society of Cardiology

    Dr Angela Pirillo

  132. Statins and Oxidative Stress During Atherogenesis

    Article • European Journal of Cardiovascular Prevention & Rehabilitation, June 2003, Wolters Kluwer Health

    Dr Angela Pirillo

  133. Article • Journal of Cardiovascular Risk, June 2003, Wolters Kluwer Health

    Dr Angela Pirillo

  134. Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini

    Article • Biochemical Journal, March 2002, Portland Press Ltd.

    Dr Angela Pirillo

  135. Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini

    Article • Biochemical Journal, March 2002, Portland Press Ltd.

    Dr Angela Pirillo

  136. Overexpression of Inducible Heat Shock Protein 70 in COS-1 Cells Fails to Protect From Cytotoxicity of Oxidized LDLs

    Article • Arteriosclerosis Thrombosis and Vascular Biology, March 2001, Wolters Kluwer Health

    Dr Angela Pirillo

  137. Modification of high density lipoproteins: Effects on OxLDL cytotoxicity and on cholesterol efflux

    Article • Atherosclerosis, July 2000, Elsevier

    Dr Angela Pirillo

  138. Enhanced Macrophage Uptake of Elastase-Modified High-Density Lipoproteins

    Article • Biochemical and Biophysical Research Communications, May 2000, Elsevier

    Dr Angela Pirillo

  139. Oxidized Lipoproteins and Endothelium

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2000, De Gruyter

    Dr Angela Pirillo

  140. Oxysterols from oxidized LDL are cytotoxic but fail to induce hsp70 expression in endothelial cells

    Article • FEBS Letters, November 1999, Wiley

    Dr Angela Pirillo

  141. Procyanidines from vitis vinifera seeds protect low density lipoproteins from oxidation

    Article • Atherosclerosis, May 1999, Elsevier

    Dr Angela Pirillo

  142. Endothelium and oxidised lipoproteins

    Article • Atherosclerosis, May 1999, Elsevier

    Dr Angela Pirillo

  143. Chronic stimulation by insulin induces HSP60 expression in cultured eahy cells

    Article • Atherosclerosis, May 1999, Elsevier

    Dr Angela Pirillo

  144. Overexpression of HSP72 in COS-1 cells does not protect from apoptosis induced by oxidized LDL

    Article • Atherosclerosis, May 1999, Elsevier

    Dr Angela Pirillo

  145. 3.P.87 Two distinct components of oxidized LDL mediate the heat shock response and cytotoxicity triggered by OxLDL

    Article • Atherosclerosis, October 1997, Elsevier

    Dr Angela Pirillo

  146. 3.P.255 Cholesterol biosynthesis pathway is involved in the heat shock protein and cytotoxic indicated by oxidized LDL in cultured human endothelial cells and smooth muscle cells

    Article • Atherosclerosis, October 1997, Elsevier

    Dr Angela Pirillo

  147. Simvastatin Modulates the Heat Shock Response and Cytotoxicity Mediated by Oxidized LDL in Cultured Human Endothelial Smooth Muscle Cells

    Article • Biochemical and Biophysical Research Communications, February 1997, Elsevier

    Dr Angela Pirillo

  148. Human Endothelial Cells Exposed to Oxidized LDL Express hsp70 Only When Proliferating

    Article • Arteriosclerosis Thrombosis and Vascular Biology, September 1996, Wolters Kluwer Health

    Dr Angela Pirillo

  149. Oxidized Ldl Trigger the Expression of Hsp70 in Cultured Endothelial Cells

    Article • January 1996, Springer Science + Business Media

    Dr Angela Pirillo

  150. Oxidized LDL induce hsp70 expression in human smooth muscle cells

    Article • FEBS Letters, September 1995, Wiley

    Dr Angela Pirillo

  151. Oxidized lipoproteins induce long-lasting inhibition of nitric oxide synthase from a murine endothelioma cell line (bEnd.4)

    Article • Journal of Cardiovascular Risk, April 1995, Wolters Kluwer Health

    Dr Angela Pirillo

  152. Oxidized Lipoproteins Induce Long-Lasting Inhibition of Nitric Oxide Synthase from a Murine Endothelioma Cell Line (bEnd.4)

    Article • European Journal of Cardiovascular Prevention & Rehabilitation, April 1995, SAGE Publications

    Dr Angela Pirillo

  153. Constituents of Nothapodytes foetida

    Article • Journal of the Chemical Society Perkin Transactions 1, January 1995, Royal Society of Chemistry

    Dr Angela Pirillo